{"id":693,"date":"2012-12-01T12:04:00","date_gmt":"2012-12-01T11:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2012\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren"},"modified":"2022-03-17T14:12:33","modified_gmt":"2022-03-17T13:12:33","slug":"angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2012\/angiooedem-unter-ace-hemmern-und-anderen-renin-angiotensin-inhibitoren","title":{"rendered":"Angio\u00f6dem unter ACE-Hemmern und anderen Renin-Angiotensin-Inhibitoren"},"content":{"rendered":"<p>Das Angioneurotische \u00d6dem oder Angio\u00f6dem ist eine seltene, aber potenziell gef\u00e4hrliche unerw\u00fcnschte Arzneimittelwirkung (UAW) bei Einnahme von Angiotensin-Konversions-Enzym (ACE)-Hemmern (ACE-H; vgl. 1). Das ACE wandelt das Blutdruck-inaktive Angiotensin I (A I) in das aktive A II um. Au\u00dferdem wirkt es als Kininase, die den Abbau von Bradykinin f\u00f6rdert. Es wird vermutet, dass Angio\u00f6deme unter Therapie [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Das Angioneurotische \u00d6dem oder Angio\u00f6dem ist eine seltene, aber potenziell gef\u00e4hrliche unerw\u00fcnschte Arzneimittelwirkung (UAW) bei Einnahme von Angiotensin-Konversions-Enzym (ACE)-Hemmern (ACE-H; vgl. 1). Das ACE wandelt das Blutdruck-inaktive Angiotensin I (A I) in das aktive A II um. Au\u00dferdem wirkt es als Kininase, die den Abbau von Bradykinin f\u00f6rdert. Es wird vermutet, dass Angio\u00f6deme unter Therapie [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[130,1108,1733,1732,316,309,312,314,313,315,317,320,311,307,319,310,129,128,131,306],"class_list":["post-693","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-ace-hemmer","tag-aliskiren","tag-angioneurotisches-oedem","tag-angiooedem","tag-angiotensin-ii-antagonisten","tag-angiotensin-ii-blocker","tag-angiotensin-ii-inhibitoren","tag-angiotensin-ii-rezeptor-antagonisten","tag-angiotensin-ii-rezeptor-blocker","tag-angiotensin-ii-rezeptor-inhibitoren","tag-at-ii-antagonisten","tag-at-ii-blocker","tag-at-ii-inhibitoren","tag-at-ii-rezeptor-antagonisten","tag-at-ii-rezeptor-blocker","tag-at-ii-rezeptor-inhibitoren","tag-beta-blocker","tag-betablocker","tag-betarezeptoren-blocker","tag-sartane"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=693"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/693\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=693"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=693"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}